longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Vitrafy Life Sciences Ltd. (VFY) Gets a Buy from Ord Minnett

Tip Ranks
Feb 16, 2026 at 04:45 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Ord Minnett analyst Tom Godfrey has maintained a Buy rating on Vitrafy Life Sciences Ltd. (VFY) with a price target of A$2.50. Godfrey, a 5-star analyst, has an average return of 47.5% and a success rate of 52.17%. The current analyst consensus on Vitrafy is a Moderate Buy, with an average price target of A$2.38.

Ord Minnett analyst Tom Godfrey maintained a Buy rating on Vitrafy Life Sciences Ltd. today and set a price target of A$2.50.

President's Day Sale - 70% Off

  • Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
  • Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Godfrey is a 5-star analyst with an average return of 47.5% and a 52.17% success rate. Godfrey covers the Healthcare sector, focusing on stocks such as Paragon Care Limited, Trajan Group Holdings Ltd, and Australian Clinical Labs Ltd.

Currently, the analyst consensus on Vitrafy Life Sciences Ltd. is a Moderate Buy with an average price target of A$2.38.

Login to unlock229characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Vita Life Sciences Limited

Vita Life Sciences Limited

VLS.AU

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--

LongbridgeAI